Research evidence The pivotal efficacy evidence comes from two identically designed Phase 3 randomized placebo-controlled trials run by Theratechnologies and reported by Julian Falutz and colleagues in the New England Journal of Medicine in 2007 (Falutz et al., NEJM 357:2359-2370)
Milk thistle (Silybum marianum) is a Mediterranean plant whose seeds contain silymarin, a group of antioxidant plant compounds
Scientific interest grew because laboratory investigations suggested Body Protection Compound-157 influences several biological processes associated with tissue repair and cellular recovery
Not intended to diagnose, treat, cure, mitigate, or prevent disease
Pharmacies sourcing USP-grade copper peptide with Certificate of Analysis documentation from accredited suppliers charge more than those using less rigorously tested raw materials
Clinical trial protocols from the Phase 2 NEJM study used a gradual escalation approach, starting at low doses and increasing every four weeks